(Press-News.org) Contact information: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
'Undruggable' mutation meets its match
6-year effort yields first drug to target important cancer gene
	In the field of drug design, the protein K-Ras is legendary. It's been on everyone's "target" list for more than 30 years due to its status as the most commonly mutated oncogene in human cancers. Despite this high profile, K-Ras has earned a reputation in scientific circles as being "undruggable" because many pharmaceutical, biotech, and academic laboratories have failed to design a drug that successfully targets the mutant gene.
Now, Howard Hughes Medical Institute (HHMI) researchers at the University of California, San Francisco have identified and exploited a newfound "Achilles heel" in K-Ras. The weak point is a newly discovered "pocket," or binding site, identified by HHMI investigator Kevan M. Shokat and colleagues. Shokat and his team have designed a chemical compound that fits inside this pocket and inhibits the normal activity of mutant K-Ras, but leaves the normal protein untouched. 
"K-Ras is considered to be the most important oncogene in cancer and is widely believed to be 'undruggable,'" said Shokat. "We report the discovery of a new pocket on K-Ras that is druggable. We believe this has real translational implications for patients."
In a research article published November 20, 2013, in the journal Nature, Shokat's team describes a novel chemical compound that fits into a previously unknown pocket in K-Ras and interferes with function of the enzyme. The Ras proteins are small GTPase enzymes that transmit signals within cells. They are critical to cells because of the central role they play in cell growth and survival. 
The name Ras also refers to the family of genes encoding those proteins. One of those genes, K-Ras, which was discovered nearly 30 years ago, is mutated in 30 percent of human tumors, including 90 percent of pancreatic cancers, 40 percent of colon cancers, and 20 percent of non-small cell lung cancers. Cancers with Ras mutations are aggressive and respond poorly to standard therapies.
Despite setbacks in targeting mutant Ras genes, the National Cancer Institute (NCI) recently emphasized the continued importance of this elusive drug target by announcing a focused $10 million effort, dubbed the RAS project, to bring together researchers to develop new ideas for blocking Ras. The project aims to spur development of new drugs or therapies to benefit patients with cancer. 
Shokat's HHMI team, which is not part of the NCI initiative, started working on Ras in earnest about six years ago. Using their expertise in chemistry, Shokat and two team members -- Ulf Peters, a postdoctoral fellow, and Jonathan Ostrem, an MD-PhD student -- sketched out some early ideas for a new class of drugs that inhibit Ras mutants. "Some of the early strategies did not work," he said. "We had to develop a new kind of screen and that ultimately led to progress in developing this new inhibitor."
Shokat says they did a few things differently when defining the scope of their attack. They kept their focus narrow, being mindful of strategies that had not worked for other scientists. They also chose to study a type of K-Ras mutant called G12C (for Glycine-12 to Cysteine), a K-Ras mutant prevalent in about seven percent of patients with lung cancer. (The K-Ras gene is mutated in 20 percent of lung cancer cases, and G12C is the most frequent mutation of K-Ras.) 
This mutation causes a substitution of the amino acid cysteine for glycine at position 12 in the K-Ras protein. Importantly, this cysteine sits in a location critical for the normal function of Ras. In another departure from previous efforts, Shokat and his colleagues did not try to target versions of Ras that had mutations in the amino acids aspartate and valine – which are relatively common and hence where a lot of scientists had focused their attention previously. Instead, they picked G12C mutants because those Ras mutants affected a large population of lung and colorectal cancer patients (over 20,000 new patients each year in the US alone) and because they had a cysteine substitution. 
Shokat says the presence of this cysteine conveyed certain chemical properties that gave his team a unique handle for drug design. Cysteine is unique among the 20 natural amino acids in its ability to form covalent bonds. Most commonly bonds are made between two cysteines to stabilize protein structure, but if a free cysteine is present, as in G12C K-Ras, a specifically designed drug can form a bond to the cysteine.
"Everybody else (developing drug design strategies) had been thinking they had to go after all the Ras mutants," Shokat says. "We looked for what no else had done and we picked this particular mutation because of its chemical properties."
Over a three-year period, the team developed a preliminary screen with more than 500 chemical compounds to see if they could identify one that would bind covalently and "tether" with K-Ras G12C. Their studies led to the identification of a potent inhibitor of K-Ras. To get a better picture of how this compound interacted with K-Ras, the scientists solved crystal structures of the compound bound to K-Ras. When they examined the data, Shokat and his team found a previously undescribed pocket on the surface of K-Ras near the cysteine residue. "This pocket is new," Shokat says. "No one had found it before."
Investigating further, they found that the compound interferes with Ras in such a way that it alters its natural affinity for its substrate GTP, but not GDP. "One of the most important aspects of this is that this small molecule inhibits only mutant K-Ras and not the normal protein," Shokat says.
Next steps include continuing to optimize this compound so that it can be further tested to see how well the compound kills cancer cells with the G12C mutation. Shokat said he and his colleagues have started a company called Araxes Pharma, LLC., which has entered into a partnership with Janssen Biotech, a division of Johnson & Johnson, to develop these compounds for potential clinical use.
### END
'Undruggable' mutation meets its match
6-year effort yields first drug to target important cancer gene
2013-11-21
ELSE PRESS RELEASES FROM THIS DATE:
Drug strategy blocks a leading driver of cancer
2013-11-21
Drug strategy blocks a leading driver of cancer
UCSF researchers solve decades-old challenge
	The protein in cells that most often drives the development of cancers has eluded scientists' efforts to block it for three decades — until now. 
	Using ...
Long-term unemployment may accelerate aging in men
2013-11-21
Long-term unemployment may accelerate aging in men
	Men who are unemployed for more than two years show signs of faster ageing in their DNA, a new study has found.
	Researchers at Imperial College London and the University of Oulu, Finland studied DNA samples ...
Recessions experienced in mid-life linked to higher risk of cognitive decline later on
2013-11-21
Recessions experienced in mid-life linked to higher risk of cognitive decline later on
Enforced job loss, part time working, and lower paid, lower status jobs may all take their toll
	Lay-offs and enforced part time work and lower paid, lower status jobs ...
Too much weekly sport seems to be as bad as too little for teen wellbeing
2013-11-21
Too much weekly sport seems to be as bad as too little for teen wellbeing
But maximum benefit gained from double official recommendation on physical activity
	But the maximum benefit seems to be obtained from 14 hours of sport a week, which is double the ...
Excessive testosterone raises mortality risk in older men
2013-11-21
Excessive testosterone raises mortality risk in older men
Study pinpoints optimal testosterone range for longer lifespan
	Chevy Chase, MD—Older men whose testosterone levels were neither low nor high tended to live longer, according to new research accepted ...
Metabolically healthy obesity does not guarantee clean bill of health
2013-11-21
Metabolically healthy obesity does not guarantee clean bill of health
High BMI linked to increased risk of diabetes, cardiovascular disease
	Chevy Chase, MD—Obese people who are currently metabolically healthy face a higher risk of developing diabetes and ...
International Tree Nut Council funded study links nut consumption to reduced death rate
2013-11-21
International Tree Nut Council funded study links nut consumption to reduced death rate
Largest study to date on nut consumption and mortality in New England Journal of Medicine
	In a study published today in the New England Journal of Medicine, researchers looked ...
Mount Sinai finds brain abnormalities linked to impaired self-awareness in cocaine addiction
2013-11-21
Mount Sinai finds brain abnormalities linked to impaired self-awareness in cocaine addiction
Study challenges stigmatizing assumptions about cocaine addicted-individuals, points to targeted treatments based on quantifiable ...
PTSD raises risk for obesity in women
2013-11-21
PTSD raises risk for obesity in women
Women with PTSD gain weight more rapidly than women without disorder
	Women with post-traumatic stress disorder (PTSD) gain weight more rapidly and are more likely to be overweight or obese than ...
The last croak for Darwin's frog
2013-11-21
The last croak for Darwin's frog
	Deadly amphibian disease chytridiomycosis has caused the extinction of Darwin's frogs, believe scientists from the Zoological Society of London (ZSL) and Universidad Andrés Bello (UNAB), Chile.
	Although habitat disturbance ...
LAST 30 PRESS RELEASES:
Cobalt single atom-phosphate functionalized reduced graphene oxide/perylenetetracarboxylic acid nanosheet heterojunctions for efficiently photocatalytic H2O2 production
World-first study shows Australian marsupials contaminated with harmful ‘forever chemicals’
Unlocking the brain’s hidden drainage system
Enhancing smoking cessation treatment for people living with HIV
Research spotlight: Mapping how gut neurons respond to bacteria, parasites and food allergy
Gordon and Betty Moore Foundation Experimental Physics Investigators awards to UCSB experimentalists opens the door to new insights and innovations
Meerkats get health benefit from mob membership
COVID-19 during pregnancy linked to higher risk of neurodevelopmental disorders in children
How a chorus of synchronized frequencies helps you digest your food
UAlbany researcher partners on $1.2 million NSF grant to explore tropical monsoon rainfall patterns
Checkup time for Fido? Wait might be longer in the country
Genetic variation impact scores: A new tool for earlier heart disease detection
The Lundquist Institute awarded $9 million to launch Community Center of Excellence for Regenerative Medicine
'Really bizarre and exciting': The quantum oscillations are coming from inside
Is AI becoming selfish?
New molten salt method gives old lithium batteries a second life
Leg, foot amputations increased 65% in Illinois hospitals between 2016-2023
Moffitt studies uncover complementary strategies to overcome resistance to KRAS G12Cinhibitors in lung cancer
National summit of experts charts unprecedented roadmap to reduce harms from firearms in new ways
Global environmental DNA (eDNA) surveys significantly expand known geographic and ecological niche ranges of marine fish, highlighting current biases in conservation and ecological modeling
Hundreds of animal studies on brain damage after stroke flagged for problematic images
Prize winner’s research reveals how complex neural circuits are correctly wired during brain development
Supershear rupture sustained in thick fault zone during 2025 Mandalay earthquake, study in research package shows
Study reveals how brain cell networks stabilize memory formation
CTE: More than just head trauma, suggests new study
New psychology study suggests chimpanzees might be rational thinkers
Study links genetic variants to higher 'bad' cholesterol and heart attack risk
Myanmar fault had ideal geometry to produce 2025 supershear earthquake
Breakthrough in BRCA2 research: a novel mechanism behind chemoresistance discovered
New funding for health economics research on substance use disorder treatments
[Press-News.org] 'Undruggable' mutation meets its match6-year effort yields first drug to target important cancer gene